Managed Healthcare Executive1d
The Benefits of Self-Insurance and ERISA’s Role in Employer Health Plans
Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a ...
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Zacks.com on MSN4d
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
FDA accepts Alnylam’s sNDA for vutrisiran for ATTR-CM treatment
Pharmaceuticals announced that the U.S. Food and Drug Administration or FDA, has accepted for review the Company’s supplemental ...
Monthly Prescribing Reference5d
Vutrisiran Under Review for Transthyretin Amyloid Cardiomyopathy
Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...
BioSpace5d
Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Le Lézard5d
VUZE Medical Showcases Concurrent Multi-Tool 3D Guidance in Spine Surgery, With No Navigational Hardware and Using Standard Pre-Op CT
VUZE Medical, a privately-held company aiming to transform intra-operative guidance in spinal interventions currently aided only by 2D X-ray, has recently demonstrated concurrent software-based 3D ...
pharmaphorum5d
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...